Mixed Performance for Dx Firms' Stocks in November as 360Dx Index Rises 2 Percent

Dec 03, 2018

|

NEW YORK (360Dx)– Stocks of many diagnostics firms rebounded in November from a difficult prior month as the 360Dx Index rose almost 2 percent month over month.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Mixed Performance for Dx Firms' Stocks in November as 360Dx Index Rises 2 Percent

To read the full story....

Breaking News

Calciscon Raises $2.7M in Series A Round

PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

Ethos Labs, Agena Biosciences Partner on SARS-CoV-2 Variant Identification

Danaher Expects Q1 2021 Revenue Growth Above Previous Guidance

Australian Firm AnteoTech Obtains CE Marking for COVID-19 Antigen Test, Reader

What's Popular?

Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

Danaher Expects Q1 2021 Revenue Growth Above Previous Guidance

DiaSorin to Acquire Luminex for $1.8B

Ortho Clinical Diagnostics Gets Additional CE Mark for Coronavirus Antigen Test

Sponsorships